Programmable singlet oxygen battery and uses thereof

The programmable singlet oxygen battery addresses PDT limitations by storing ROS pre-therapy and releasing it on demand at the tumor site, improving treatment efficacy and minimizing side effects.

WO2026240708A1PCT designated stage Publication Date: 2026-11-19NATIONAL UNIVERSITY OF SINGAPORE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/SG2026/050301
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Photodynamic therapy (PDT) is limited by tumor hypoxic environments and insufficient light penetration depth, leading to reduced efficacy against deep-seated tumors, and existing ROS battery systems exhibit uncontrolled 'always-ON' ROS release, causing side effects.

Method used

A programmable singlet oxygen battery (SOB) comprising pyridone compounds encapsulated in a metal organic framework (MOF), which stores ROS pre-therapy and releases it on demand within the tumor microenvironment, featuring an 'OFF-ON-OFF' ROS release behavior.

Benefits of technology

The SOB achieves precise ROS delivery to therapeutic sites with minimal side effects by storing ROS for extended periods, rapidly releasing it at the tumor site, and ceasing release post-therapy, enhancing treatment efficacy while reducing off-target cytotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SG2026050301_19112026_PF_FP_ABST
    Figure SG2026050301_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure concerns a singlet oxygen battery (SOB), comprising a first pyridone compound and a second pyridone compound encapsulated in a metal organic framework (MOF); wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with singlet oxygen (1O2); wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of a reducing agent and / or copper ions in order to release 1O2. The disclosure also concerns a method of fabricating the SOB and a method of treating cancer, a tumor and / or a microbial infection.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Programmable Singlet Oxygen Battery and Uses Thereof

[0002] Technical Field

[0003] The present invention relates, in general terms, to programmable singlet oxygen battery and their uses thereof.

[0004] Background

[0005] Photodynamic therapy (PDT) has been explored as a non-invasive, high-efficiency cancer treatment strategy that kills cancer cells by using photosensitizers (PSs) to generate reactive oxygen species (ROS). Importantly, this mechanism allows PDT to be effective against cancers that have developed multi-drug resistance to traditional chemotherapeutics. However, tumor hypoxic environment has become a significant problem that limits the application of PDT, as traditional photosensitization processes employ oxygen dependent approaches. Specifically, for type-II PSs, oxygen is intrinsically consumed to form singlet oxygen, resulting in a highly oxygen-dependent photosensitization pro-cess. On the other hand, type-I PSs provide a different photosensitization process with lower oxygen-dependence. However, since oxygen is intrinsically needed for both Type-I and Type-II PS-based PDT, the tumor hypoxic environment (oxygen concentration varied from 0-2%) would inevitably affect the treatment effect of PDT utilizing these photosensitization pro-cesses.

[0006] Another issue for PDT treatment is the limited light penetration depth. Traditional PDT employs visible and near-infrared (NIR) light, with absorption peaks tailored to PSs, resulting in a penetration depth of 0.5-2 mm into the skin or tumor tissue. NIR-II light PDT could be achieved by PSs with two-photon absorption, with a penetration depth up to 2-10 mm. However, it remains insufficient for treating deep-seated or large tumors, which require penetration depths of several centimeters, depending on the tumor location and size. This limitation is particularly pronounced in the treatment of bulky tumors or internal malignancies, such as lung metastasis cancer.

[0007] To address this issue, there is a growing interest in ROS production throughalternative energy sources that offer deeper tissue penetration, such as Sonodynamic Therapy (SDT) and X-ray-induced Photodynamic Therapy (X-PDT). These modalities can achieve tissue penetration up to several centimeters. However, it's important to note that both SDT and X-PDT typically rely on indirect excitation pathways, so that the ROS production efficiency can be compromised. Therefore, successful application of SDT and X-PDT requires specific PSs.

[0008] It would be desirable to overcome or ameliorate at least one of the abovedescribed problems.

[0009] Summary

[0010] The present disclosure provides a singlet oxygen battery (SOB), comprising a first pyridone compound and a second pyridone compound encapsulated in a metal organic framework (MOF);

[0011] wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with singlet oxygen (¹O₂);

[0012] wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of a reducing agent and / or copper ions in order to release ¹O₂.

[0013] In some embodiments, the first pyridone compound and the second pyridone compound are configured to couple to each other via a click reaction in the presence of the reducing agent and / or copper ions.

[0014] In some embodiments, the first pyridone compound is represented by Formula (la):

[0015]

[0016] wherein R₁ is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy;

[0017] R3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy; and

[0018] n is an integer selected from 1 to 3.

[0019] In some embodiments, the second pyridone compound is represented by Formula (lb):

[0020]

[0021] wherein Ri is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy;

[0022] Rj is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy; and

[0023] n is an integer selected from 1 to 3.

[0024] In some embodiments, the first pyridone compound and the second pyridone compound are separately coupled with1O₂.

[0025] In some embodiments, the first pyridone compound is coupled with1O₂. In some embodiments, the second pyridone compound is coupled with1O₂.

[0026] In some embodiments, when coupled to1O2, the first pyridone compound is characterized by a half-life of more than 7 h. In some embodiments, when coupled to1O₂, the second pyridone compound is characterized by a half-life of more than 7 h.

[0027] In some embodiments, the MOF is a copper-based MOF.

[0028] In some embodiments, the MOF is selected from MOF-199, HKUST-1, PCN-6, PCN-222(Cu), Cu-BTC, Cu-TCPP, or a combination thereof.

[0029] In some embodiments, the first pyridone compound and the second pyridone compound are loaded in MOF at a loading of about 20% w / w to about 50% w / w.

[0030] In some embodiments, when coupled to1O₂, the singlet oxygen battery is characterized by a half-life of at least 40 h.

[0031] In some embodiments, when the singlet oxygen battery is in the presence of a reducing agent and / or copper ions, the singlet oxygen battery is characterized by a half-life of less than 30 min.

[0032] The present disclosure also provides a method of fabricating a singlet oxygen battery (SOB), comprising:

[0033] encapsulating a first pyridone compound and a second pyridone compound in a metal organic framework (MOF);

[0034] wherein at least one of the first pyridone compound and the second pyridone compound is couple-able withXO2;

[0035] wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of a reducing agent and / or copper ions in order to releaseXO2-

[0036] In some embodiments, the method further comprises a step of reacting the first pyridone compound and the second pyridone compound with1O₂ in order to independently couple the first pyridone compound and the second pyridone compound with1O₂.

[0037] In some embodiments,1O₂ is generated in situ by irradiating a photosensitizer.

[0038] In some embodiments, the photosensitizer is methylene blue, Rose Bengal, indocyanine green (ICG), IR780, Chlorin e6 (Ce6), porphyrin derivatives, or a combination thereof.

[0039] In some embodiments, the encapsulation step comprises mixing the first pyridone compound and the second pyridone compound with MOF precursors.

[0040] In some embodiments, the method further comprises a step of covering the MOF encapsulated first and second pyridone compounds with a lipid membrane.

[0041] The present disclosure also provides a method of releasing singlet oxygen (1O2) from the singlet oxygen battery (SOB), comprising the step of contacting the SOB with a reducing agent and / or copper ions.

[0042] In some embodiments, the reducing agents is selected from ascorbate, tris(2-carboxyethyl) phosphine (TCEP), NADH, NADPH, thiosulfate, metallic copper, hydroquinone, vitamin K1, glutathione (GSH), cysteine, 2-mercaptoethanol, dithiothreitol, Fe2+, Co2+, N-acetylcysteine (NAC), dithiocarbamate compounds, thioredoxin (Trx), endogenous enzymes (e.g., glutaredoxin), and an applied electric potential.

[0043] The present disclosure also provides a pharmaceutical composition comprising the singlet oxygen battery, or a pharmaceutically acceptable salt or solvate thereof.

[0044] The present disclosure also provides a method of treating cancer, a tumor and / or a microbial infection in a subject in need thereof, comprising administering a therapeutically effective amount of the singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof to the subject.

[0045] The present disclosure also provides a singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof for use in treating cancer, a tumor and / or a microbial infection.

[0046] The present disclosure also provides a use of the singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of cancer, a tumor and / or a microbial infection.

[0047] In some embodiments, the cancer or tumor is selected from pancreatic ductal adenocarcinoma (PDAC), lung metastases, hepatocellular carcinoma, breast cancer (e.g., 4T1), cervical cancer (HeLa), colorectal cancer, and melanoma.

[0048] Brief description of the drawings

[0049] Embodiments of the present invention will now be described, by way of nonlimiting example, with reference to the drawings in which:

[0050] Figure 1. Illustration of the design rationale of sterically control PSOB enabled by singlet oxygen " A-B gel" strategy.

[0051] Figure 2. Different singlet oxygen storage capability of Py-A, Py-B and Py-AB. A-I) ESI-MS spectrum of Py-A, Py-B and Py-AB before, after white light irradiation for 30 min and then stored in dark for 1 h. (aqueous solution, 5 pM Py-A, Py-B, Py-AB). J)1H NMR (D₂O: H₂O = 1: 19 with water suppression) of SOB-A, SOB-B before and after stored in 37 °C for 40 h and the changing ratio of SOB-A and Py-A in solution referring to the integral change of peak Hb (chemical shift from 6.0-6.5). K)1H NMR (D₂O: H₂O = 1: 9 with water suppression) of SOB-B, Py-B before and after stored in 37 °C for 40 h and the changing ratio of SOB-A and Py-A in solution referring to the integral change of peak Hb (chemical shift from 6.0-6.5).

[0052] Figure 3. Sterically control singlet oxygen storage capability of SOB-A, SOB-B and SOB-AB. A) UV-Vis absorption of Py-A, Py-B and Py-AB (10 pM in PBS); B) UV-Vis absorption spectrum of formation of SOB-A, SOB-B, SOB-AB from 40 min irradiation of white light (>300 nm, 40 mW / cm2) of Py-A, Py-B and Py-AB; C) Absorption peak intensity change of Py-A, Py-B, Py-AB under 40 min irradiation of white light; D) UV-Vis absorption spectrum change of SOB-A and SOB-B stored in dark and hypoxic environment. E) Absorption peak intensity change of SOB-A, SOB-B, SOB-AB stored in dark for 40 h; F) UV-Vis. absorption spectrum change of SOB-AB stored in dark and hypoxic environment. G) Absorption peak intensity change of SOB-AB stored in dark for 40 min; H) Fluorescent emission change of SOSG at 535 nm incubated with SOB-A+Cu(I) (Cu(MeCN)4PF6, 10 pM), SOB-B+Cu(I), SOB-A& B, SOB-A& B+Cu(I) for 35 min; I) Fluorescent emission change of SOSG at 535 nm incubated with SOB-A& B under different pH.

[0053] Figure 4.XO2 storage and release behavior of A-B@PMOFs. A) BET characteristics of MOF-199 and A-B@PMOF, and A-B@PMOF+10 mM GSH; B) SEM characteristics of A-B@MOF, A-B@PMOF and after incubation of 10 mM GSH for 5 min; C) Fluorescent emission change at 530 nm of SOSG incubated with A-B@PMOF, A-B solution and A-B@PMOF treated with TFA; D. XRD characteristics of MOF-199, A-B@PMOF, A-B@PMOF+GSH and A-B@PMOF+TFA.

[0054] Figure 5. Intracellular ROS production and cell viability. A) ROS detection (SOSG as indicator) Fluorescence imaging of PANC-1 cells treated with PBS, SOB-A& B (5 pM SOB-A and 5 pM SOB-B), SOB-A& B+CU + (5 pM SOB-A and 5 pM SOB-B and 5 pM Cu(MeCN)4PF6), A-B@PMOF, A-B@PMOF+BSO; B) 3T3 cells treated with PBS, SOB-A& B (5 pM SOB-A and 5 pM SOB-B), SOB-A& B+Cu + (5 pM SOB-A and 5 pM SOB-B and 5 pM Cu(MeCN)4PF6), A-B@PMOF, A-B@PMOF+GSH. Scale bar: 20 pm. C) Dose-dependent cytotoxicity of SOB-A& B, SOB-A& B+CU+, A-B@PMOF and A-B@PMOF+BSO to PANC-1 cells; D), Dosedependent cytotoxicity of SOB-A& B, SOB-A&B+Cu+, A-B@PMOF and A-B@PMOF+BSO to 3T3 cells; E) Dose-dependent cytotoxicity of A-B@PMOF to A549, HepG2, HeLa, 4T1, L929 and HEK293 cells.

[0055] Figure 6. Antitumor efficacy on Panc-02 tumor model. A) Illustration of the treatment process of Panc-02 tumor model, and the mice in G1-G4 were administered with different formulations (saline, PMOF, SOB-A& B NP, A-B@PMOF) for 3 times, every 2 d and evaluated until Day 21. B) Tumor weight of G1-G4 at the end of treatments.

[0056] Detailed description

[0057] The present disclosure is predicated on the understanding that Singlet Oxygen Battery (SOB) system is a promising strategy for addressing the challenges associated with hypoxic tumor environments and limited light penetration. This approach involves the use of molecules, such as pyridone or anthracene derivatives, capable of storing ROS generated by PSs in vitro, followed by their release in vivo, facilitating oxygen and light-independent ROS therapy. So far, the reported ROS battery systems predominantly feature pyridone structures throughout the storage and release stages, leading to a constant "always-ON" ROS release behaviour, with the release rate solely dependent on the half-life of pyridone endoperoxides (EPO), which varied from several minutes to severalhours. The continuous release of ROS after in-vivo administration unavoidably led to side effects.

[0058] For example, a previous report described a 2-pyridone-based diblock polymer (PEG-Py) to achieve1O₂-based afterglow therapy. Another reported a metalorganic framework-based poly-pyridone system poly-mPYR to deliverXO2. Another introduced a targeted SOB with a pyridone-based CARG-1O₂ for treatment of bacterial deep-tissue infections. So far, the reported ROS battery systems predominantly feature pyridone structures through-out the storage and release stages, leading to a constant "always-ON" ROS release behaviour, with the release rate solely dependent on the half-life of pyridone endoperoxides (EPO), which was around 1.8 min for PEG-Py and around 8 h for poly-mPYR. The continuous release of ROS after in vivo administration unavoidably led to side effects.

[0059] It is believed that an ideal ROS battery system should exhibit an " OFF-ON-OFF" ROS release behaviour across three critical stages:

[0060] (1) Storage Stage (OFF): In this stage, the SOB demonstrates a long term ROS storage behaviour during blood circulation, minimizing side effects and preventing premature ROS leakage before it approaches the tumor cells;

[0061] (2) Release Stage (ON): Upon reaching the tumor microenvironment (TME), the system transitions to a rapid and comprehensive ROS release, maximizing the efficiency of ROS therapy; and

[0062] (3) Exhaust Stage (OFF): Post-therapy and prior to excretion from the body, the ROS battery is turned off or becomes exhausted, ceasing any further ROS release to mitigate post-treatment side effects.

[0063] The on-demand switching system is thus advantageous to realize programmed control over ROS release. This system would enable the transition between long term storage pre-therapy and rapid release within the tumor microenvironment, followed by ceased1O₂ release post-therapy, tailoring the ROS therapy to the specific temporal and spatial requirements of the treatment.

[0064] Accordingly, the present disclosure concerns a series of pyridone-based

[0065] programmable singlet oxygen battery with tunable1O₂ storage capability, which can store1O₂ pre-therapy (long half-live, several days) and selectively activate their fast1O₂ release capability (several minutes) in therapeutic site. These batteries showed great potential in precision disease treatment, such as tumor therapy and bacteria ablation.

[0066] This allows the singlet oxygen battery of the present disclosure to exhibit relatively longXO2 storage half-lives pre-therapy, and precisely deliver1O₂ to the desired therapeutic site, and quickly and selectively release1O₂ for treatment of tumor or acne, then cease1O₂ release post-therapy to avoid further side-effect post-therapy. This "OFF-ON-OFF" targeted1O₂ release behaviour is superior to traditional "Always-ON" SOBs with higher therapeutic outcomes and lower side-effects.

[0067] Accordingly, the present disclosure provides a singlet oxygen battery (SOB), comprising a first pyridone compound and a second pyridone compound encapsulated in a metal organic framework (MOF);

[0068] wherein the first pyridone compound and the second pyridone compound are configured to independently couple with1O₂;

[0069] wherein in the presence of a reducing agent and / or copper ions, the first pyridone compound and the second pyridone compound are configured to couple to each other and release1O₂.

[0070] In some embodiments, the singlet oxygen battery (SOB) comprises a first pyridone compound and a second pyridone compound encapsulated in a metal organic framework (MOF);

[0071] wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with singlet oxygen (1O₂);

[0072] wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of a reducing agent and / or copper ions in order to release1O₂.

[0073] The SOB of the present disclosure avoids the use of pyridone-based polymers, which is disadvantageous as pyridone-based polymers exhibited1O₂ release behaviour in a continuous, 'always-on' manner, and lacking spatiotemporalcontrol. This uncontrolled release may lead to premature1O₂ leakage in normal tissues both before and after therapy, thereby increasing the risk of off-target cytotoxicity and associated side effects.

[0074] In some embodiments, the first and second pyridone compounds are each independently coupled with1O₂. For instance, the singlet oxygen may be coupled to an exemplary pyridone compound at the 3,6 position as shown below to form an oxygen bridge:

[0075]

[0076] In some embodiments, the pyridone compound is represented by Formula (I):

[0077]

[0078] wherein Ri is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy;

[0079] R2 is selected from azidyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy;

[0080] R3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy; and

[0081] n is an integer selected from 1 to 3.

[0082] " Alkyl" refers to monovalent alkyl groups which may be straight chained or branched and preferably have from 1 to 10 carbon atoms or more preferably 1 to 6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, and the like.

[0083] " Alkenyl" refers to a monovalent alkenyl group which may be straight chained or branched and preferably have from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and have at least 1 and preferably from 1-2, carbon to carbon, double bonds. Examples include ethenyl (-CH=CH2), n-propenyl (-CH2CH=CH2), / so-propenyl (-C(CH3)=CH2), but-2-enyl (-CH2CH = CHCH3), and the like.

[0084] " Alkoxy" refers to the group alkyl-O- where the alkyl group is as described above. Examples include, methoxy, ethoxy, n-propoxy, / so-propoxy, n-butoxy, tert- butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

[0085] " Cycloalkyl" refers to cyclic alkyl groups having a single cyclic ring or multiple condensed rings, preferably incorporating 3 to 11 carbon atoms. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, indanyl, 1,2, 3, 4-tetrahydronapthalenyl and the like.

[0086] " Aryl" refers to an unsaturated aromatic carbocyclic group having a single ring (eg. phenyl) or multiple condensed rings (eg. naphthyl or anthryl), preferably having from 6 to 14 carbon atoms. Examples of aryl groups include phenyl, naphthyl and the like.

[0087] " Heteroaryl" refers to a monovalent aromatic heterocyclic group which fulfils the Huckel criteria for aromaticity (ie. contains 4n + 2 n electrons) and preferably has from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen, selenium, and sulfur within the ring (and includes oxides of sulfur, selenium and nitrogen). Such heteroaryl groups can have a single ring (eg. pyridyl, pyrrolyl or N-oxides thereof or furyl) or multiple condensed rings (eg. indolizinyl, benzoimidazolyl, coumarinyl, quinolinyl, isoquinolinyl or benzothienyl).

[0088] Examples of heteroaryl groups include, but are not limited to, oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine,

[0089] isoindole, indole, indazole, purine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, isothiazole, phenoxazine, phenothiazine, thiazole, thiadiazoles, oxadiazole, oxatriazole, tetrazole, thiophene, benzo[b]thiophene, triazole, imidazopyridine and the like.

[0090] In this specification "optionally substituted" is taken to mean that a group may or may not be further substituted or fused (so as to form a condensed polycyclic group) with one or more groups selected from hydroxyl, acyl, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy, amino, aminoacyl, thio, arylalkyl, arylalkoxy, aryl, aryloxy, carboxyl, acylamino, cyano, halogen, nitro, phosphono, sulfo, phosphorylamino, phosphinyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, oxyacyl, oxime, oxime ether, hydrazone, oxyacylamino, oxysulfonylamino, aminoacyloxy, trihalomethyl, trialkylsilyl, pentafluoroethyl, trifluoromethoxy, difluoromethoxy, trifluoromethanethio, trifluoroethenyl, mono- and di-alkylamino, mono-and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and diheteroarylamino, mono- and di-heterocyclyl amino, and unsymmetric disubstituted amines having different substituents selected from alkyl, aryl, heteroaryl and heterocyclyl, and the like, and may also include a bond to a solid support material, (for example, substituted onto a polymer resin). For instance, an "optionally substituted amino" group may include amino acid and peptide residues.

[0091] In some embodiments, R2 comprises a chemical handle. The first pyridone compound may have a first chemical handle, while the second pyridone compound may have a second and complementary chemical handle. For example, R2 may be a chromophore which can conjugate with another chromophore or fluorophore.

[0092] The term "chemical handle" as used herein, refers to a functional group that is capable of undergoing a click reaction, a 1,3-dipolar cycloaddition, and / or a Staudinger ligation. Nonlimiting exemplary chemical handles include alkynereactive moieties, such as azide; and azide-reactive moieties, such as alkynes,including, but not limited to, terminal alkynes and activated alkynes; and phosphines, including, but not limited to, a triarylphosphine; and the like.

[0093] The term "complementary chemical handle" as used herein, refers to a functional group that is capable of undergoing a click reaction, a 1,3-dipolar cycloaddition, and / or a Staudinger ligation with a specified chemical handle. For example, for an azide chemical handle, complementary chemical handles include, but are not limited to, alkynes, such as terminal alkynes and activated alkynes, and phosphines, such as triarylphosphines.

[0094] The terms "click chemistry" and "click reaction" as used herein, refer to copper ion-catalyzed 1,3-dipolar cycloadditions between an azide and a terminal alkyne to form a 1,2,3-triazole. Azides and terminal alkynes can undergo Cu(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC) at room temperature. Such Cu(I)-catalyzed azide-alkyne cycloadditions, sometimes referred to as click chemistry, typically results in formation of a 1,2,3-triazole. Various exemplary click reactions are known in the art, and are described, e.g., in U.S. Publication No. 2005 / 0222427, the reference of which is herein incorporated.

[0095] The term "1,3-dipolar cycloaddition" as used herein, refers to reactions between an azide and an alkyne to form a 1,2,3-triazole.

[0096] In some embodiments, the first pyridone compound and the second pyridone compound are capable of undergoing a click reaction or click chemistry. In this regard, the R2 moiety of the first and second pyridone compounds are complementary. In some embodiments, R2 is optionally substituted azide. In some embodiments, R2 is optionally substituted alkynyl. The coupling of the first and second pyridone compounds may thus be a copper-catalysed azide-alkyne cycloaddition click reaction.

[0097] In some embodiments, the first pyridone compound is represented by Formula (la):

[0098]

[0099] In some embodiments, the second pyridone compound is represented by Formula (lb):

[0100]

[0101] Thus, when the first pyridone is coupled to the second pyridone, the coupled compound may be:

[0102]

[0103] In some embodiments, Ri is independently selected from H, optionally substituted alkyl. In some embodiments, R1 is independently optionally substituted alkyl. In some embodiments, R1 is independently optionally substituted C1-C5 alkyl. In some embodiments, Ri is independently optionally substituted methyl or optionally substituted ethyl. In some embodiments, Ri in both Formula (I) and (II) is optionally substituted methyl or optionally substituted ethyl.

[0104] In some embodiments, R3 is independently selected from H, optionally substituted alkyl. In some embodiments, R3 is independently optionally substituted alkyl. In some embodiments, R3 is independently optionally substituted C1-C5 alkyl. In some embodiments, R3 is independently optionally substituted methyl or optionally substituted ethyl. In some embodiments, R3 is independently H. In some embodiments, R3 in both Formula (I) and (II) is optionally substituted methyl or optionally substituted ethyl. In some embodiments, R3 in both Formula (I) and (II) is H.

[0105] Accordingly, in some embodiments, the singlet oxygen battery comprises a first pyridone of Formula (la) and a second pyridone of Formula (lb) encapsulated in a metal organic framework

[0106]

[0107]

[0108] wherein the first pyridone compound and a second pyridone compound are configured to independently couple withXO2;

[0109] wherein in the presence of a reducing agent and / or copper ions, the first pyridone compound and a second pyridone compound undergo click reaction with each other to releaseXO2.

[0110] In some embodiments, the singlet oxygen battery comprises a first pyridone of Formula (la) and a second pyridone of Formula (lb) encapsulated in a metal organic framework (MOF):

[0111]

[0112] wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with1O2;

[0113] wherein the first pyridone compound and a second pyridone compound are couple-able with each other in the presence of a reducing agent and / or copper ions in order to release1O2.

[0114] In some embodiments, the first pyridone compound is couple with *02 as represented by Formula (lai):

[0115]

[0116] (lai).

[0117] It was found that this compound is relatively stable.

[0118] In some embodiments, the second pyridone compound is couple withxOz as represented by Formula (Ibi):

[0119]

[0120] It was found that this compound is relatively stable.

[0121] In some embodiments, the first pyridone compound is coupled withXO2. In some embodiments, the second pyridone compound is coupled with1O2. In some embodiments, both the first pyridone compound and the second pyridone compound are separately coupled with!O2.

[0122] In some embodiments, when coupled to O2, the first pyridone compound is characterized by a half-life of more than 7 h. In some embodiments, the first pyridone compound is characterized by a half-life of more than 8 h, 9 h or 10 h. In some embodiments, the first pyridone compound is characterized by a half-life of about 7 h to about 15 h, about 8 h to about 15 h, about 9 h to about 15 h, or about 10 h to about 15 h.

[0123] In some embodiments, when coupled toXO2, the second pyridone compound is characterized by a half-life of more than 7 h. In some embodiments, the second pyridone compound is characterized by a half-life of more than 8 h, 9 h or 10 h. In some embodiments, the second pyridone compound is characterized by a half-life of about 7 h to about 15 h, about 8 h to about 15 h, about 9 h to about 15 h, or about 10 h to about 15 h.

[0124] In some embodiments, when coupled to O2, the first pyridone compound is characterized by a stability across a pH range of about 3 to about 10.

[0125] In some embodiments, when coupled toXO2, the second pyridone compound is characterized by a stability across a pH range of about 3 to about 10.

[0126] The first pyridone compound and a second pyridone compound are encapsulated in a metal organic framework (MOF). It was found that the MOF advantageously serves as the nanoconfined carrier to stabilize first pyridone and second pyridone compound when coupled toXO2 pre-therapy. The integration of MOF and the singlet oxygen carriers may also help enhance the storage lifetime of the battery.

[0127] In some embodiments, the first pyridone compound and the second pyridone compound are loaded in MOF at a loading of about 20% w / w to about 50% w / w. In some embodiments, the loading is about 25% w / w to about 50% w / w, about 30% w / w to about 50% w / w, about 30% w / w to about 45% w / w, or about 30% w / w to about 40% w / w. In some embodiments, the loading is about 35% w / w.

[0128] The copper ions may be provided by a copper ion source. The copper ion source may be any source of Cu(I) ions, whether or not formation of Cu(I) ions involves other agents, such as reducing agents. Nonlimiting exemplary copper ion sources include copper salts, such as Cu(NO3)2 Cu(OAc)2 or CuSO4; copper halides, such as CuBr and Cui; and copper-containing metals, such as copper wire.

[0129] In some embodiments, the copper ions are Cu(I) ions. Exemplary sources of Cu(I) ions include, but are not limited to, cuprous halides such as cuprous bromide or cuprous iodide. In some embodiments, the Cu(I) is generated in situ from Cu(II) ions and a reducing agent. Cu(II) is reduced to Cu(I) in situ. Exemplary sources of Cu(II) ions include, but are not limited to, Cu(NO3)2, Cu(OAc)2, and CuSO4. Nonlimiting exemplary reducing agents include ascorbate, tris(2-carboxyethyl) phosphine (TCEP), NADH, NADPH, thiosulfate, metallic copper, hydroquinone, vitamin K1, glutathione (GSH), cysteine, 2-mercaptoethanol, dithiothreitol, Fe2+, Co2+, and an applied electric potential. Insome embodiments, a reducing agent is a metal selected from Al, Be, Co, Cr, Fe, Mg, Mn, Ni, Zn, Au, Ag, Hg, Cd, Zr, Ru, Fe, Co, Pt, Pd, Ni, Rh, and W.

[0130] In some embodiments, the MOF comprises copper. For example, the MOF may comprise Cu(II) and / or Cu(I) ions. In some embodiments, the MOF is a copperbased MOF. Copper ions may thus be released by degradation of MOF, causing the first pyridone compound and a second pyridone compound to couple to each other and release1O₂. TheXO2 may thus be released from the first pyridone compound, from the second pyridone compound or from both.

[0131] In some embodiments, the MOF is selected from MOF-199, HKUST-1, PCN-6, PCN-222(Cu), Cu-BTC, Cu-TCPP, or a combination thereof. These MOFs contain Cu(II) centers capable of being reduced to Cu(I) under tumor microenvironment conditions, enabling controlled collapse and catalytic click activation.

[0132] For example, when the MOF comprises Cu(II) ions, contact with a reducing agent such as glutathione (GSH) causes the reduction of Cu(II) to Cu(I) and the MOF to degrade. This releases the first pyridone compound and the second pyridone compound. The presence of Cu(I) concurrently also catalyses the click reaction between the first pyridone compound and the second pyridone compound, thereby releasingxOz from the singlet oxygen battery.

[0133] In some embodiments, when coupled to1O₂, the singlet oxygen battery is characterized by a half-life of at least 40 h. In some embodiments, the singlet oxygen battery is characterized by a half-life of at least 45 h, 50 h, 55 h, 60 h, 65 h, or 70 h.

[0134] Advantageously, when the first pyridone compound and the second pyridone compound are coupled to form SOB-AB, it exhibits a fast decomposition rate, thus releasingXO2 quickly.

[0135] In some embodiments, when the singlet oxygen battery is in the presence of a reducing agent and / or copper ions, the singlet oxygen battery is characterized by a half-life of less than 30 min. In some embodiments, the half-life is lessthan 25 min, 20 min, 15 min, 10 min, or 5 min. In some embodiments, the halflife is less than 9 min.

[0136] The present disclosure also provides a method of fabricating a singlet oxygen battery (SOB), comprising:

[0137] encapsulating the first pyridone compound and the second pyridone compound in a metal organic framework (MOF);

[0138] wherein the first pyridone compound and the second pyridone compound are configured to independently couple withXO2;

[0139] wherein in the presence of a reducing agent and / or copper ions, the first pyridone compound and the second pyridone compound are configured to couple to each other and release1O₂.

[0140] In some embodiments, the method of fabricating a singlet oxygen battery (SOB) comprises:

[0141] encapsulating the first pyridone compound and the second pyridone compound in a metal organic framework (MOF);

[0142] wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with singlet oxygen (1O₂);

[0143] wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of a reducing agent and / or copper ions in order to releaseXO2-

[0144] In some embodiments, the method further comprises a step of reacting the first pyridone compound and / or the second pyridone compound withXO? in order to independently couple the first pyridone compound and / or the second pyridone compound withXO2. The coupling step of the first pyridone compound withXO2 may be conducted separately from the coupling step of the second pyridone compound withXO2, or the coupling step of the first and second pyridone compounds may be performed together. This step may be performed after the first and second pyridone compounds are encapsulated in MOF, or preferably before their encapsulation.

[0145] In some embodiments,XO? is generated in situ. For example,XO? may be generated by irradiating a photosensitizer. In some embodiments, the

[0146] photosensitizer is a Type I or II photosensitizer. In some embodiments, the photosensitizer is methylene blue, Rose Bengal, indocyanine green (ICG), IR780, Chlorin e6 (Ce6), porphyrin derivatives, or a combination thereof. These photosensitizers may efficiently generate singlet oxygen upon light irradiation and are biocompatible.

[0147] In some embodiments, the encapsulation step comprises mixing the first pyridone compound and the second pyridone compound with MOF precursors. For example, a one-pot de-novo synthesis may be performed where the first and second pyridone compounds are mixed with MOF-199 precursors (e.g., Cu(NO3)2and benzene-l,3,5-tricarboxylic acid) in ethanol or DMF, followed by stirring for 20 min. The resultant MOF nanocrystals encapsulate SOB-A and SOB-B within their porous frameworks, with a typical loading efficiency of 30-40%.

[0148] In some embodiments, the method further comprises a step of covering or encapsulating the MOF encapsulated first and second pyridone compounds with a lipid membrane or in a lipid vesicle or liposome. This enhances the stability of the SOB. For example, the MOF-encapsulated pyridone compounds may be coated with cancer cell membranes using a sonication and extrusion method. The procedure involves isolating membrane vesicles from Panc02 cells, mixing them with A-B@MOF nanoparticles, and extruding through a 200 nm polycarbonate membrane to form a biomimetic outer layer. The successful coating was confirmed using TEM. This coating improves systemic stability, prolongs circulation time, and enables tumor-specific homotypic targeting.

[0149] The present disclosure also provides a method of releasing singlet oxygen O2) from the singlet oxygen battery (SOB), comprising the step of contacting the SOB with a reducing agent and / or copper ions. In some embodiments, the reducing agents is selected from ascorbate, tris(2-carboxyethyl) phosphine (TCEP), NADH, NADPH, thiosulfate, metallic copper, hydroquinone, vitamin K1, glutathione (GSH), cysteine, 2-mercaptoethanol, dithiothreitol, Fe2+, Co2+, N-acetylcysteine (NAC), dithiocarbamate compounds, thioredoxin (Trx), endogenous enzymes (e.g., glutaredoxin), and an applied electric potential. These agents may act alone or synergistically with glutathione to reduce Cu(II)to Cu(I), destabilizing the MOF framework and triggering click activation. In some embodiments, the copper ions are Cu(I) ions.

[0150] The present disclosure also provides a pharmaceutical composition comprising the singlet oxygen battery, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition further comprises an excipient.

[0151] The present disclosure also provides a method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof to the subject.

[0152] The present disclosure also provides a singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof for use in treating cancer.

[0153] The present disclosure also provides a use of the singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of cancer.

[0154] The present disclosure also provides a method of treating a tumor and / or a microbial infection in a subject in need thereof, comprising administering a therapeutically effective amount of the singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof to the subject.

[0155] The present disclosure also provides a singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof for use in treating a tumor and / or a microbial infection.

[0156] The present disclosure also provides a use of the singlet oxygen battery or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a tumor and / or a microbial infection.

[0157] The SOB demonstrates long1O2storage capability pre-therapy, low1O2leakage and minimal side-effect pre-therapy. Fast release1O2behaviour in tumor oracne site was observed. For example, at the tumor site, the SOB responses to tumor microenvironment to yield Cu(I), which catalyzes the click reaction of the first and second pyridone compounds and quickly release1O2. This allows for targeted1O2therapy with high therapeutic outcome, independent of oxygen supply and light irradiation.

[0158] The tumor microenvironment (TME) is a complex ecosystem surrounding a tumor, composed of cancer cells, stromal tissue (including blood vessels, immune cells, fibroblasts and signaling molecules) and the extracellular matrix. Mutual interaction between cancer cells and the different components of the tumor microenvironment support its growth and invasion in healthy tissues which correlates with tumor resistance to current treatments and poor prognosis. The tumor microenvironment is in constant change because of the tumor's ability to influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can affect the growth and evolution of cancerous cells.

[0159] A tumor's vasculature is important to its growth, as blood vessels deliver oxygen, nutrients, and growth factors to the tumor. Tumors smaller than 1-2 mm in diameter are delivered oxygen and nutrients through passive diffusion. In larger tumors the center becomes too far away from the existing blood supply, leading the tumor microenvironment to become hypoxic and acidic. Angiogenesis is upregulated to feed the cancer cells and is linked to tumor malignancy.

[0160] In hypoxic environments the tissue sends out signals called hypoxia inducible factors (HIFs) that can stimulate nearby endothelial cells to secrete factors such as vascular endothelial growth factor (VEGF). VEGF activates the endothelial cells, which begins the process of angiogenesis, where new blood vessels emerge from pre-existing vasculature. The blood vessel formed in the tumor environment often does not mature properly, and as a result the vasculature formed in the tumor microenvironment differs from that of normal tissue. The blood vessels formed are often "leaky" and tortuous, with a compromised bloodflow. As tumors cannot grow large without proper vasculature, sustained angiogenesis is therefore considered one of the hallmarks of cancer.

[0161] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is selected from pancreatic ductal adenocarcinoma (PDAC), lung metastases, hepatocellular carcinoma, breast cancer (e.g., 4T1), cervical cancer (HeLa), colorectal cancer, and melanoma. These tumors are characterized by hypoxia, high glutathione levels, or poor responsiveness to conventional PDT, making them suitable for SOB therapy.

[0162] In some embodiments, the microbial infection is acne. In some embodiments, the microbial infection is a drug resistant bacterial infection. The bacteria may be Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and E. coli. The infection may be a deep tissue infection or biofilm. The singlet oxygen released from SOBs may be capable of destroying bacterial membranes and proteins via oxidative damage, even in hypoxic or light-inaccessible sites.

[0163] Acne, also known as acne vulgaris, is a skin condition that occurs when dead skin cells and oil from the skin clog hair follicles. It may be caused by hormonal changes, sebaceous glands oil over-production, clogged pores, and inflammation caused by bacteria. The types of acne includes comedones (such as whiteheads and blackheads), and inflammatory lesions (such as papules, pustules, nodules, and cysts). In treating acne, the SOB targets Cutibacterium acnes (formerly Propionibacterium acnes) through localized1O2release. The SOB system accumulates in inflamed sebaceous follicles, where elevated glutathione levels or local reducing agents activate rapid1O2release, inducing oxidative bacterial killing and reducing inflammation. This mechanism bypasses the need for light exposure and addresses antibiotic resistance issues.

[0164] The present disclosed SOB may thus be used as a1O2targeted delivery reagent for1O2treatment of tumor or bacteria infection. As shown herein, the presently disclosed compounds and / or composite has a significant killing effect on deep-seated hypoxic tumor, independent of oxygen supply and light irradiation, and may become an alternative to traditional photodynamic therapy for clinical treatment of tumor and acne.

[0165] The SOB can be administered to a subject as a pharmaceutically acceptable salt thereof. Suitable pharmaceutically acceptable salts include, but are not limited to salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, maleic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benezenesulphonic, salicyclic sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.

[0166] Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium. In particular, the present invention includes within its scope cationic salts eg sodium or potassium salts, or alkyl esters (eg methyl, ethyl) of the phosphate group.

[0167] Basic nitrogen-containing groups may be quarternised with such agents as lower alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.

[0168] The SOB may be in crystalline form either as the free compound or as a solvate (e.g. hydrate) and it is intended that both forms are within the scope of the present invention. Methods of solvation are generally known within the art.

[0169] The SOB, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the patient in a therapeutically effective amount. As used herein, a therapeutically effective amount is intended to include at least partially attaining the desired effect, or delaying the onset of, or inhibiting the progression of, or halting or reversing altogether the onset or progression of macular degeneration.

[0170] The term "therapeutic effect" refers to some extent of relief of one or more of the symptoms of a disorder (e.g., a neoplasia or tumor) or its associated

[0171] pathology. " Therapeutically effective amount" as used herein refers to an amount of an agent which is effective, upon single or multiple dose administration to the cell or subject, in prolonging the survivability of the patient with such a disorder, reducing one or more signs or symptoms of the disorder, preventing or delaying, and the like beyond that expected in the absence of such treatment. " Therapeutically effective amount" is intended to qualify the amount required to achieve a therapeutic effect. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the "therapeutically effective amount" (e.g., ED50) of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in a pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0172] As used herein, the term "effective amount" relates to an amount of compound which, when administered according to a desired dosing regimen, provides the desired therapeutic activity. Dosing may occur at intervals of minutes, hours, days, weeks, months or years or continuously over any one of these periods. Suitable dosages may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage, such as is in the range of 1 mg to 1 g per kg of body weight per dosage. In one embodiment, the dosage may be in the range of 1 mg to 500 mg per kg of body weight per dosage. In another embodiment, the dosage may be in the range of 1 mg to 250 mg per kg of body weight per dosage.

[0173] Suitable dosage amounts and dosing regimens can be determined by the attending physician and may depend on the severity of the condition as well as the general age, health and weight of the patient to be treated.

[0174] The SOB may be administered in a single dose or a series of doses. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a composition, preferably as a pharmaceutical composition. The formulation of such compositions is well known to those skilled in the art. The composition may contain any suitable carriers, diluents or excipients. Theseinclude all conventional solvents, dispersion media, fillers, solid carriers, coatings, antifungal and antibacterial agents, dermal penetration agents, surfactants, isotonic and absorption agents and the like. It will be understood that the compositions of the invention may also include other supplementary physiologically active agents.

[0175] The carrier must be pharmaceutically "acceptable" in the sense of being compatible with the other ingredients of the composition and not injurious to the patient. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

[0176] The SOB may also be suitable for intravenous administration. For example, the SOB or a pharmaceutically acceptable salt, solvate or prodrug thereof may be administered intravenously at a dose of up to 100 mg / m2.

[0177] The SOB may also be suitable for oral administration and may be presented as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. In another embodiment, the SOB or a pharmaceutically acceptable salt, solvate or prodrug is orally administerable.

[0178] A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g inert diluent, preservative disintegrant (e.g. sodium starch glycolate, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersingagent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

[0179] The SOB may be suitable for topical administration in the mouth including lozenges comprising the active ingredient in a flavoured base, usually sucrose and acacia or tragacanth gum; pastilles comprising the active ingredient in an inert basis such as gelatine and glycerin, or sucrose and acacia gum; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0180] The SOB may be suitable for topical administration to the skin may comprise the compounds dissolved or suspended in any suitable carrier or base and may be in the form of lotions, gel, creams, pastes, ointments and the like. Suitable carriers include mineral oil, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Transdermal patches may also be used to administer the compounds of the invention.

[0181] The SOB may be suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bactericides and solutes which render the compound, composition or combination isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The SOB may be presented in unitdose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0182] Preferred unit dosage composition is those containing a daily dose or unit, daily sub-dose, as herein above described, or an appropriate fraction thereof, of the active ingredient.

[0183] It should be understood that in addition to the active ingredients particularly mentioned above, the composition may include other agents conventional in the art having regard to the type of composition in question, for example, those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents disintegrating agents, coating agents, preservatives, lubricants and / or time delay agents. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include cornstarch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable flavouring agents include peppermint oil, oil of Wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include polymers or copolymers of acrylic acid and / or methacrylic acid and / or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl di stea rate.

[0184] Examples

[0185] Programmable Singlet Oxygen Batteries for precise1O2therapy

[0186] The present subject matter is direct to the development and use of pyridone-based singlet oxygen battery as the backbone, store1O2in its pristine state, and response to tumor microenvironment or inflammation microenvironment to release1O2. The backbone of SOB (i.e. pyridone compound which is the carrier of the singlet oxygen) is shown as Formula (I):

[0187]

[0188] wherein R.i and R2 are independently selected from the group of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,alkoxy group and as well as one or more chromophores which can conjugate with one or more fluorophores. R.2 may be either azide or alkyne. R.2 may be at a 3' position relative to N.

[0189] The pyridone compound may be optionally substituted 1-3 times, with any one of alkyl, alkenyl, alkynyl, amino, cycloalkyl, aryl, heteroaryl, and alkoxy.

[0190] In an example as shown in Figure 1, the inventors developed series a programmable singlet oxygen batteries for targetedXO2 delivery. Commercially available type-II photosensitizer MB (methylene blue) was used as theXO2 donor, while MOF serving as the nanoconfined carrier to stabilize SOB-A and SOB-B pre-therapy from Py-A and Py-B respectively. SOB-A and SOB-B refers to the pyridone form with singlet oxygen stored as an oxygen bridge. After loaded the1O2produced by MB, SOB-A and SOB-B were encapsulated by MOF to form A-B@MOF, and then covered with cell membrane to enhance the stability to form A-B@PMOF. The efficacy of this system was evaluated through in vivo experiments using a subcutaneous mice model of subcutaneous Panc02 tumors and orthotopic Panc-02-luci tumor model. At the tumor site, MOF responses to tumor microenvironment to yield or release Cu(I) from its framework, which catalyzes the click reaction of SOB-A and SOB-B to form SOB-AB and quickly release1O2. The results demonstrated antitumor effect with high spatiotemporal selectivity and the potential of A-B@PMOF as a light and oxygen-free PDT agent. These findings provide new insights into modulating the stability of metastable oxygen bridges in PSOBs by constructing dynamic steric hindrance at the bridgehead carbon. This approach improves therapeutic efficiency and minimizes the side effects, independent of light irradiation and oxygen supply.

[0191] In Figure 1, SOB-A and SOB-B were substituted by linear group ethynyl and azide group at position 3 bridgehead carbon, respectively. The synthesis to Py-A starts from 3-iodide pyridone, the first step was N-methylation with methyl iodomethane, to give compound 2 with 96.2 % yield. Then compound 2 undergoes typically Sonnogashira reaction with trimethylsilylacetylene, followed by reaction with tetrabutylammonium fluoride to eliminate trimethylsilyl group to give Py-A. The synthesis of Py-B starts from l-methyl-3-amino pyridone withone step synthesis through 3-position substitution of azide group. SOB-A and SOB-B was synthesized separately, from Py-A and Py-B with irradiation of Methylene Blue (MB) in CH2CI2 solution and followed by extraction of H2O to separate SOB-A and SOB-B. The SOB-AB with large steric hinderance was synthesized by SOB-A and SOB-B with typical CuAAC (copper-catalysed azidealkyne cycloaddition) click reaction with 83% yield. These compounds were fully characterized by1H nuclear magnetic resonance (NMR),13C NMR and high-resolution mass spectrum (HR-MS) to reveal their right structures with high purity.

[0192] In SOB-A and SOB-B, 3-position bridgehead carbon was substituted by linear ethynyl and azide groups with relatively small steric hinderance, respectively. For SOB-AB, the bridgehead carbon was substituted by cyclic triazole group, which brings larger steric hinderance. To investigate the steric driven differences of1O2storage capability of SOB-A, SOB-B and SOB-AB, ESI-MS and1H-NMR was used to monitor the singlet oxygen storage and release behaviours. Firstly, ESI-MS was utilized to illustrate the storage capability of SOBs in a qualitative manner. As shown in Figure 2A, ESI-MS spectra of Py-A (original pyridone form of SOB-A) exhibit a mass-to-charge peak at 134.0602 ([M + H]+). Upon incubation with MB, and subsequently irradiated by white light led to the disappearance of original peak of Py-A, and formation of a new peak at 166.0505 (Figure 2B), which indicates the thoroughly transformation from Py-A to SOB-A ([M+O2+H]+). After stored in dark and hypoxic environment for 1 h, as depicted in Figure 2C, the peak of SOB-A maintained, indicating the stability and1O2storage capability of SOB-A. In addition, another bridgehead carbon linear substituted pyridone SOB-B exhibited similar stable1O2storage capability with SOB-A, in its pristine solution, the ESI-MS spectra showed a mass-to-charge peak at 151.0622 ([M + H]+), after incubation of MB and white light irradiation, the peak shifted to 166.0505 ([M+O2+H]+), indicating formation of SOB-B, and after subsequent storage in dark for 1 h, the peak of SOB-B maintained. These data indicates that SOB-A and SOB-B with small linear substitution at bridgehead carbon is relatively stable. On the contrary, SOB-AB with larger cyclic substitution group at bridge head carbon, exhibited fast decompose rate. As shown in Figure 2G-I, after incubated with MB under irradiation of white light for 30 min, the formation of new peak of SOB-AB andremnant peak of Py-AB (Py-A coupled to Py-B) indicates that Py-AB was partly transformed to SOB-AB. In addition, when stored in dark for 1 h, the peak referred to SOB-AB disappeared completely, indicating the fast decompose rate of SOB-AB. This evidence indicates that SOB-A and SOB-B with small steric hinderance at bridgehead carbon is favorable for1O2storage, while SOB-AB with larger cyclic steric hinderance is capable for1O2release. On the other hand,1H NMR was utilized to investigate the half-lives of SOB-A, SOB-B and SOB-AB from a quantitative view. As presented in Figure 2J and 2K,1H NMR of SOB-A, SOB-B and SOB-AB solution when stored in dark was monitored to evaluate their half-lives, respectively. When incubated in dark for 40 h, a notable shift of resonance peak of Hb was observed, which transformed from a sp3 carbon to a sp2 carbon, resulting in a significant chemical shift during1O2release behaviour of SOBs, makes it a good marker for1O2release behaviour monitoring. For quantification, the initial integral of Hb at each SOB was set to "1". The subsequent decrease of integral of Hb during 40 h incubation was used to construct the SOB decomposition curve (Figure 2J and 2K). In addition, based on the decomposition curves of SOB-A, SOB-B and SOB-AB, the half-lives of them were evaluated. For SOB-A and SOB-B with linear substitution, they have relatively long half-lives, which are 10.5 h and 8.7 h, respectively. On the other hand, for SOB-AB with cyclic substitution, the SOB exhibited a much shorter half-live, which is 9.5 min. These data represent the distinct1O2storage capability between SOB-A and SOB-B with smaller steric hinderances and SOB-AB with a larger steric hinderance from both qualitative and quantitative point of view. In conclusion, linear substituted SOB-A and SOB-B have relative high stability, which is favorable of1O2storing, while cyclic substituted SOB-AB has a much shorter half-life, which makes it good for1O2releasing.

[0193] The1O2storage and release behaviour of SOBs involves the destruction and reconstruction of the conjugated structure of pyridones, resulting in significant changes in their absorption spectra. UV-vis spectroscopy was employed to monitor these behaviours in SOB-A, SOB-B, and SOB-AB. As shown in Figure 3A, Py-A and Py-B exhibit broad absorption peaks centered at 280 nm and 320 nm, respectively, while Py-AB displays a red-shifted absorption peak at 375 nm due to its larger conjugated structure. Upon incubation with 10 pM MB and exposure to white light (40 mW / cm2, 40 min), the absorption intensity of Py-A,Py-B, and Py-AB decreased progressively, reaching a minimum at 30 minutes (Figure 3C).1O2release was further investigated by tracking UV-Vis spectra during light irradiation and MB incubation. In a dark, hypoxic environment, the initial absorption of SOB-A and SOB-B gradually increased, reaching a maximum at ~35 hours (Figure 3D). In contrast, SOB-AB demonstrated rapid1O2release within 40 minutes (Figures 3F and 3G). These differences in1O2storage align with ESI-MS and 1H NMR data (Figure 2).

[0194] The Cu(I)-promoted1O2release behaviour of the SOB-A& B system was also examined. As shown in Figure 2H, SOB-A and SOB-B alone, incubated with Cu(I), exhibited negligible changes in SOSG fluorescence, indicating slow1O2release. Similarly, a mixed solution of SOB-A and SOB-B showed minimal1O2release. However, when the SOB-A& B mixture was incubated with Cu(I), SOSG fluorescence significantly increased, indicating rapid1O2release. ESI-MS spectra revealed a new peak at 316.1044, corresponding to SOB-AB, confirming its formation during Cu(I) incubation as the cause of accelerated ^2 release.

[0195] Furthermore, the SOB-A& B mixed solution exhibited stability across a pH range of 3-10 and in the presence of various ions under biological conditions, demonstrating its highly specific responsiveness to Cu(I).

[0196] Following the evaluation of the intrinsic1O2storage capability of SOBs, their1O2release behaviours were tested after being loaded into MOF-199 (A-B@PMOF). MOF-199, and A-B@PMOF were successfully synthesized. SOB-A and SOB-B effectively loaded into MOF-199 via de-novo synthesis (loading ratio: 34.2 %). BET analysis (Figure 4A) revealed a reduced adsorbed volume for A-B@PMOF compared to pristine MOF-199, confirming successful loading. Upon treatment with 10 mM glutathione (GSH) for 5 minutes, the adsorbed volume decreased to nearly 0 cm3 / g, and the morphologies of A-B@MOF and A-B@PMOF were completely destroyed (Figure 4B), indicating full degradation of the MOF framework. Additionally, A-B@PMOF exhibited rapid1O2release in the presence of 10 mM GSH.

[0197] The mechanism of GSH-activated1O2release was investigated using ESI-MS. Within 5 minutes of GSH addition, a new peak at 316.1044 appeared,

[0198] corresponding to SOB-AB formation. After 30 minutes, the disappearance of the SOB-AB peak and emergence of a Py-AB peak indicated that SOB-AB rapidly decomposed to release1O2, yielding Py-AB. This process explains the fast1O2release triggered by GSH.

[0199] TheXO2 storage behaviour of A-B@PMOF was further evaluated. Compared to the intrinsicXO2 storage capability of SOB-A& B, the half-life ofXO2 storage in A-B@PMOF extended significantly to ~60 hours. To explore this unexpected halflife extension, TFA was used to decompose the MOF-199 nanostructure. As shown in Figure 4C, after TFA treatment, A-B@PMOF exhibited rapid1O2release behaviour similar to that of SOB-A& B in solution. Furthermore, XRD analysis (Figure 4D) showed the complete disappearance of A-B@PMOF's characteristic peaks after 10 minutes of TFA treatment, confirming the disintegration of the MOF-199 framework. The simultaneous collapse of the MOF-199 nanostructure and recovery of SOBs' intrinsic1O2storage behaviour indicates that the MOF-199 framework induces the extended1O2storage half-life in A-B@PMOF. Prior studies have shown that nanoconfinement within MOFs influences the physical and chemical properties of loaded molecules. For SOB-A and SOB-B in solution,1O2released during the reaction dissipates into the surrounding medium, preventing significant reverse Diels-Alder recombination, thus reflecting their intrinsic storage capability (as shown in Figure 4C). However, when SOB-A and SOB-B are encapsulated within MOF's nanopores, released1O2is confined in the localized environment. This high local concentration of1O2could promotes efficient Diels-Alder recombination reaction with Py-A and Py-B to reform SOB-A and SOB-B, effectively prolonging the apparent1O2storage half-life of A-B@PMOF.

[0200] To investigate the sterically driven differences in1O2storage capabilities of SOB-A, SOB-B, and SOB-AB, the therapeutic efficacy of A-B@PMOF was evaluated in PANC-1 cancer cells and 3T3 normal cells using SOSG as a1O2indicator. Negligible fluorescence enhancement was observed in both cell types incubated with SOB-A& B alone over 2 hours, indicating slow intrinsic1O2release. However, the addition of Cu+to PANC-1 incubated with SOB-A& B triggered significant fluorescence, confirming rapid1O2release. Similarly, PANC-1 cells treated with A-B@PMOF exhibited bright fluorescence after 2 hours, demonstrating tumormicroenvironment activation. In contrast, minimal fluorescence was detected in 3T3 cells, indicating negligible1O2release in normal tissues and low side effects. To elucidate the role of GSH, L-buthionine-(S, R)-sulfoximine (BSO) was used to deplete GSH in PANC-1 cells, resulting in weak fluorescence after A-B@PMOF treatment. Conversely, excess GSH in 3T3 cells induced fluorescence similar to that in PANC-1 cells, implicating overexpressed GSH in tumor-specific1O2release. Cell viability assays further confirmed A-B@PMOF's high cytotoxicity against various cancer cells (A549, HepG2, Hela, 4T1) and low toxicity in normal cells (L929, HEK293). To compare the pre- and post-therapy side effect of A-B@PMOF with traditional " Always-ON" SOBs, 3-methyl substituted Pyridone (3-Me-SOB) was selected as the "always-ON" SOB control. When 3T3 cells were incubated with 3-Me-SOB and the1O2indicator SOSG, bright green fluorescence was observed after 1 hours, indicating significant1O2leakage pre-therapy. In contrast, 3T3 cells treated with A-B@PMOF exhibited negligible fluorescence, demonstrating minimal pre-therapy1O2release for A-B@PMOF (Figure 5B). To assess post-therapy1O2release, SOSG was added at 0 hours and 2 hours postincubation with programmable A-B@PMOF and traditional 3-Me-SOB. Both systems showed fluorescence enhancement when SOSG was added at 0 hours, confirming successful1O2release at the tumor site. However, when SOSG was introduced 1 h post-incubation, negligible fluorescence was observed in the A-B@PMOF group, while 3-Me-SOB continued to produce bright fluorescence. This result demonstrates that A-B@PMOF halts1O2release post-therapy, reducing undesirable side effects. These findings highlight A-B@PMOF's programmable "OFF-ON-OFF"1O2release behaviour, achieving high therapeutic efficacy with minimal side effects, and offering a superior alternative to traditional SOB systems.

[0201] Previous study has revealed that A-B@PMOF exhibits programmable singlet oxygen release behaviour in tumor microenvironment (TME). Further, the TME activatable1O2therapy efficacy and side effect were evaluated. Firstly, mice (five mice in each group) bearing subcutaneous Panc02 tumor was used as the animal model for the in vivo experiments (Figure 6A). To illustrate the in vivo PDT anti-tumor efficacy, the tumor volumes, weight, and the body weight of mice were continuously monitored for 21 days after treatment. Firstly, the tumors grew to approximately 80 mm3, then the mice were injected with

[0202] different formulations of G1-G4 from G1-G4, saline, PMOF, SOB-A& B NP (nanoparticle formed by SOB-A and SOB-B encapsulated by DSPE-PEG-2000) and A-B@PMOF. As shown in Figure 6, the tumor volume of mice with PMOF and SOB-A& B NP injection showed similar growth rate with mice injected with PBS, indicating that PMOF or SOB-A& B alone will not undergo fast release of1O2in tumor site and exhibited low cytotoxicity. On the contrary, there was a significant decline in the tumor size and weight of mice in G4, similar trend was also observed via the monitoring of tumor weight at the end of treatment and hematoxylin and eosin (H& E) staining of the tumors of the mice in G1-G4 groups, suggesting that A-B@PMOF was activated and showed good1O2therapy efficacy in hypoxic tumor cells.

[0203] Synthesis of compounds

[0204] Synthesis of compound Py-A

[0205] SOB-A was synthesized through a typical Sonnogashira reaction. To a 50 mL round bottom flask, a mixture of compound 2 (1 mmol, 235 mg), Pd(PPh3)2Cl2(3 mol%) and copper iodide (5% mol) was dissolved in 30 mL of triethylamine, and added dropwise to a solution of (trimethylsilyl)methylene (1.1 mmol, 107 mg) in 5 mL triethylamine. The reaction mixture was stirred at room temperature for one hour before 50 mL of ammonium fluoride solution was added. The solution was then extracted with EtOAc 50 mL for 3 times, the resulting organic phase was removed by rotary evaporation and the crude product was purified through column chromatography on silica gel with dichloromethane as eluent to give compound Py-A as a deep brown solid (83 mg, 62.1% yield).1H-NMR (400 MHz, DMSO-d6) 5 8.27 (s, 2H), 8.16 (d, J =4 Hz, 1H), 8.08 (dd, J = 5.5 Hz, 2H), 7.77 (d, J = 8 Hz, 2H), 7.64 - 7.51 (m, 4H), 7.44 (d, J = 8 Hz, 2H), 7.38 (d, J = 8 Hz, 2H), 7.34-7.30 (m, J = 6.0 Hz, 1H).

[0206] 13C NMR (100 MHz, DMSO-d6) 5 176.12, 156.79, 154.61, 151.10, 147.97, 146.88, 143.53, 131.43, 129.11, 127.14, 125.77, 125.60, 124.91, 123.86, 123.12, 122.79, 122.57, 122.30, 122.07, 121.26, 120.43, 109.30. MALDI-HRMS: m / z calcd. for [C26H17BrF6N3]+564.0510, found 564.0522.

[0207] Synthesis of compound Py-B

[0208] To a 50 mL flask compound 4 (0. 945 g, 8.6 mmol), HCI (2.5 mL) and 10 mL H2O were added under ice bath and stirred for 10 min. Then NaNO2was

[0209] dissolved in 5 mL H2O and added drop wise in 5 min. The reaction was kept in 0 °C for 30 min. Then urea (0.12 g) was added to eliminate excess NaNO2and stirred for 20 min. Then NaN3(0.90 g, 13.8 mmol) was added, the reaction was kept in 0 °C for 30 min. Then the pH of the reaction solution was adjusted to 7 by NaOH, then the product was extracted by 50 mL EtOAc for 3 times, the resulting organic phase was collected and the solvent was removed by rotary evaporation. After solvent removal, the residual was done by column chromatography on silica gel with dichloromethane=1:3 as eluent to yield Py-B as an light orange solid (1.25 g, 91.2 % yield). H-NMR (400 MHz, CD2CI2) 5

[0210] 9.62 (s, 1H), 8.39 - 8.26 (d, J = 4Hz, 2H), 8.03 (s, 1H), 7.96 (d, J = 8 Hz, 2H),

[0211] 7.62 (d, J = 8 Hz, 2H), 7.33 (d, J = 6 Hz, 2H), 7.27 - 7.11 (m, 4H), 7.06 - 6.86

[0212] (m, 6H).13C NMR (100 MHz, CD2CI2) 5 177.21, 155.50, 155.03, 151.09, 147.97, 147.30, 145.75, 143.52, 131.43, 129.70, 129.32, 126.23, 125.59, 124.90,

[0213] 124.89, 124.87, 124.62, 123.85, 123.77, 123.14, 122.29, 121.59, 121.25,

[0214] 121.17, 109.01. MALDI-HRMS: m / z calcd. for [C31H20F6N3O2]+580.1460, found 580.1475.

[0215] Synthesis of compound Py-AB

[0216] Py-AB was synthesized through a typical CuAAC click reaction. To a 50 mL round bottom flask, Py-A (133 mg, 1 mmol), Py-B ( 150 mg, 1 mmol), 5 mol% CuSO4, 15 mol% L-asorbate was dissolved in 10 mL H2O, the reaction system was protected by N2and kept in room temperature overnight. The TLC result indicated the reaction was accomplished.

[0217] Loading of1O2on Py-A, Py-B or Py-AB

[0218] Py-A, Py-B or Py-AB was loaded with singlet oxygen before loaded into MOFs. In a 50 mL three-necked flask Py-A / Py-B / Py-AB (1 mmol) was dissolved in 10 mL of DCM, MB (1 mM) in 50 pL of DCM was added. The mixture was irradiated by white light (40 mW / cm2, with <300 nm filter) for 30 min. The solvent was removed under reduced pressure and the residue was transferred to a column chromatography (PE: EA = 3:1, v:v) to afford SOB-A, SOB-B or SOB-AB (as white solids).

[0219] Loading of SOB-A and SOB-B in MOF

[0220] 1 mL of 0.1 M Cu(NO3)2aqueous solution was added to 50 mL of 1:1 (v / v) mixture of ethanol and deionized water containing 4 mM SOB-A and 4 mM SOB-B. The obtained solution was subsequently added with 1 mL of 0.1 M btc triethylammonium salt aqueous solution. The mixture was stirred vigorously at room temperature for 1 h. The resulting particles were collected by centrifugation (10000 rpm, 15 min) (10 mL of supernatants was taken to measure the absorption of SOB-A& B after loading) and washed with MeOH to yield A-B@MOF.

[0221] Release of1O2from A-B@MOF

[0222] A-B@MOF was incubated in the presence of varying concentrations of GSH (0, 0.1, 0.5, 1, 5, and 10 mM) to mimic physiological and tumor-relevant redox conditions, and the singlet oxygen was observed to be released in less than 20 min.

[0223] It will be appreciated that many further modifications and permutations of various aspects of the described embodiments are possible. Accordingly, the described aspects are intended to embrace all such alterations, modifications, and variations that fall within the spirit and scope of the appended claims.

[0224] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0225] Throughout this specification and the claims which follow, unless the context requires otherwise, the phrase "consisting essentially of", and variations such as "consists essentially of" will be understood to indicate that the recited element(s) is / are essential i.e. necessary elements of the invention. The phrase allows for the presence of other non-recited elements which do not materially affect the characteristics of the invention but excludes additional unspecified elements which would affect the basic and novel characteristics of the method defined.

[0226] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims

Claims1. A singlet oxygen battery (SOB), comprising a first pyridone compound and a second pyridone compound encapsulated in a metal organic framework (MOF);wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with singlet oxygen (1O2);wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of a reducing agent and / or copper ions in order to release ¹O₂.

2. The SOB according to claim 1, wherein the first pyridone compound and the second pyridone compound are configured to couple to each other via a click reaction in the presence of the reducing agent and / or copper ions,.

3. The SOB according to claim 1 or 2, wherein the first pyridone compound is represented by Formula (la):wherein Ri is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy;R3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy; andn is an integer selected from 1 to 3.

4. The SOB according to any one of claims 1 to 3, wherein the second pyridone compound is represented by Formula (lb):n(R^N3n N^O1Ri (lb)wherein Ri is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy;R.3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkoxy; andn is an integer selected from 1 to 3.

5. The SOB according to any one of claims 1 to 4, wherein the first pyridone compound is coupled with1O2, or the second pyridone compound is coupled with1O2, or the first pyridone compound and second pyridone compound are both coupled with1O2.

6. The SOB according to any one of claims 1 to 5, wherein when coupled to1O2, the first pyridone compound and the second pyridone compound are independently characterized by a half-life of more than 7 h.

7. The SOB according to any one of claims 1 to 6, wherein the MOF is a copper-based MOF.

8. The SOB according to any one of claims 1 to 7, wherein the MOF is selected from MOF-199, HKUST-1, PCN-6, PCN-222(Cu), Cu-BTC, Cu-TCPP, or a combination thereof.

9. The SOB according to any one of claims 1 to 8, wherein when coupled to1O2, the singlet oxygen battery is characterized by a half-life of at least 40 h.

10. The SOB according to any one of claims 1 to 9, wherein when the SOB is in the presence of the reducing agent and / or copper ions, the SOB is characterized by a half-life of less than 30 min.

11. A method of fabricating a singlet oxygen battery (SOB), comprising: encapsulating a first pyridone compound and a second pyridone compound in a metal organic framework (MOF);wherein at least one of the first pyridone compound and the second pyridone compound is couple-able with1O2;wherein the first pyridone compound and the second pyridone compound are configured to couple to each other in the presence of the reducing agent and / or copper ions in order to release1O2.

12. The method according to claim 11, wherein the method further comprises a step of reacting the first pyridone compound and the second pyridone compound within order to independently couple the first pyridone compound and the second pyridone compound with1O2.

13. The method according to claim 12, wherein1O2is generated in situ by irradiating a photosensitizer.

14. The method according to claim 13, wherein the photosensitizer is methylene blue, Rose Bengal, indocyanine green (ICG), IR780, Chlorin e6 (Ce6), porphyrin derivatives, or a combination thereof.

15. The method according to any one of claims 11 to 14, wherein the encapsulation step comprises mixing the first pyridone compound and the second pyridone compound with MOF precursors.

16. The method according to any one of claims 11 to 15, wherein the method further comprises a step of covering the MOF encapsulated first and second pyridone compounds with a lipid membrane.

17. A method of releasing singlet oxygen Ch) from the singlet oxygen battery (SOB), comprising the step of contacting the SOB according to any one of claims 1 to 10 with a reducing agent and / or copper ions.

18. The method according to claim 17, wherein the reducing agents is selected from ascorbate, tris(2-carboxyethyl) phosphine (TCEP), NADH, NADPH, thiosulfate, metallic copper, hydroquinone, vitamin K1, glutathione (GSH), cysteine, 2-mercaptoethanol, dithiothreitol, Fe2+, Co2+, N-acetylcysteine (NAC), dithiocarbamate compounds, thioredoxin (Trx), endogenous enzymes (e.g.,glutaredoxin), and an applied electric potential.

19. A pharmaceutical composition comprising the singlet oxygen battery according to any one of claims 1 to 10, or a pharmaceutically acceptable salt or solvate thereof.

20. A method of treating cancer, a tumor and / or a microbial infection in a subject in need thereof, comprising administering a therapeutically effective amount of the singlet oxygen battery according to any one of claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof to the subject.

21. A singlet oxygen battery according to any one of claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof for use in treating cancer, a tumor and / or a microbial infection.

22. Use of the singlet oxygen battery according to any one of claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of cancer, a tumor and / or a microbial infection.

23. The method, singlet oxygen battery for use and use according to any one claims 20 to 22, wherein the cancer or tumor is selected from pancreatic ductal adenocarcinoma (PDAC), lung metastases, hepatocellular carcinoma, breast cancer (e.g., 4T1), cervical cancer (HeLa), colorectal cancer, and melanoma.